Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.42 |
| ▸ | ITGAL | P20701 | 2/20 | 0.42 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | EEF2K | O00418 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10506034 | 0.81 | GAA (0.47) | GAACES2CES1ITGB2ICAM1 | |
| SCHEMBL27504078 | 0.80 | GAA (0.46) | GAACES2CES1ITGB2ICAM1 | |
| SCHEMBL6896203 | 0.79 | CES2 (0.45) | CES2CES1ITGB2ICAM1ITGAL | |
| SCHEMBL4453243 | 0.79 | GAA (0.45) | GAACES2CES1ITGB2ICAM1 | |
| SCHEMBL7470109 | 0.76 | GAA (0.49) | GAACES2CES1CNR2KCNN4 | |
| SCHEMBL7470869 | 0.73 | CYP2C19 (0.51) | CES2CES1ALDH1A1CYP2C19 | |
| SCHEMBL5685248 | 0.73 | EEF2K (0.50) | GAACES2CES1CNR2EEF2K | |
| SCHEMBL4245530 | 0.72 | GAA (0.53) | GAACES2CES1CNR2KCNN4 | |
| SCHEMBL2717119 | 0.72 | CES2 (0.40) | GAACES2CES1CNR2EEF2K | |
| SCHEMBL2832020 | 0.71 | GAA (0.45) | GAACES2CES1CNR2KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| CN-101805309-A | Benzamide derivatives as histone deacetylase inhibitors | ASTRAZENECA AB | 2010-08-18 | — | — | CN | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| CN-1642915-A | Benzamide derivatives useful as inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | GAA 119/4885CES2 238/4885CES1 131/4885 |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | GAA 168/4885CES2 223/4885CES1 110/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | GAA 98/4885CES2 230/4885CES1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.